Adragos Pharma, a global CDMO headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based provider of aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step in the expansion of its global network. Terms of the transaction were not disclosed. 
 
Baccinex, based in Courroux, Jura, Switzerland, provides sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in clinical trial supplies and small-to-medium scale commercial production.
 
Dr. Ursula Bausch, founder and CEO of Baccinex, said, “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.” 
 
Dr. Andreas Raabe, founder and CEO of Adragos Pharma, said, “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.” 
 
Dr. Ursula Bausch will continue to lead Baccinex as CEO and will remain a shareholder in the company.